EP1375495A1 - Method for producing 2-azetidinone derivative - Google Patents

Method for producing 2-azetidinone derivative Download PDF

Info

Publication number
EP1375495A1
EP1375495A1 EP02705071A EP02705071A EP1375495A1 EP 1375495 A1 EP1375495 A1 EP 1375495A1 EP 02705071 A EP02705071 A EP 02705071A EP 02705071 A EP02705071 A EP 02705071A EP 1375495 A1 EP1375495 A1 EP 1375495A1
Authority
EP
European Patent Office
Prior art keywords
group
carbon atoms
substituent
compound
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02705071A
Other languages
German (de)
French (fr)
Other versions
EP1375495B1 (en
EP1375495A4 (en
Inventor
Kouji Daiichi Pharmaceutical Co. Ltd SATO
Tsutomu Daiichi Pharmaceutical Co. Ltd YAGI
Yutaka Daiichi Pharmaceutical Co. Ltd KITAGAWA
Shigeru Daiichi Pharmaceutical Co. Ltd ICHIKAWA
Akihiro Daiichi Pharmaceutical Co. Ltd IMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of EP1375495A1 publication Critical patent/EP1375495A1/en
Publication of EP1375495A4 publication Critical patent/EP1375495A4/en
Application granted granted Critical
Publication of EP1375495B1 publication Critical patent/EP1375495B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions

Definitions

  • This invention relates to a process for producing a 2-azetidinone derivative.
  • 2-Azetidinone derivatives are important as reactive compounds for forming the subsituent at the 13-position of an anticancer compound having the following structure.
  • a reactive compound use is made of, for example, a compound (1) having the following structure (TIPS: triisopropylsilyl group, Boc: tertiary butoxycarbonyl group (hereinafter “tertiary” will be abbreviated as “t-”, i.e., “t-butoxycarbonyl group”)
  • This compound (1) is obtained by subjecting a racemic compound (2) (PMP: paramethoxyphenyl group (4-methoxyphenyl group) , Ac: acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration): to deprotection of Ac at the 3-position, conversion into TIPS, recrystallization, elimination of PMP at the 1-position, and separation by column chromatography (which will be sometimes abbreviated as column hereinafter) to give a compound (3): followed by separation with the use of an optical resolution column and attachment of a protective group.
  • a racemic compound (2) PMP: paramethoxyphenyl group (4-methoxyphenyl group)
  • Ac acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration
  • the process for obtaining the compound (1) from the racemic compound (2) suffers from a problem that troublesome procedures (epimerization, replacement of the solvent for recrystallization, isolation by the column, etc.) are needed and yet only a low yield can be achieved.
  • To obtain the compound (1) there arises an additional problem that the compound (3) should be separated by using an optical resolution column in the step prior to the final step, which results in an increase in the cost in case of mass production.
  • the present invention aims at providing a production process whereby an optically active 2-azetidinone derivative can be easily produced in a large amount at a low cost.
  • the present inventors have found a production process whereby an optically active 2-azetidinone derivative can be efficiently produced in a large amount at a low cost by treating a racemic 2-azetidinone derivative with an enzyme capable of asymmetrically hydrolyzing an ester, thereby completing the present invention.
  • the present invention relates to a process for producing a compound represented by formula (II): wherein R 1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R 2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s) , an aryloyl group
  • the present invention further relates to the followings:
  • the compound represented by formula (I) (which will be called the compound (I) hereinafter and the same will apply to compounds represented by other formulae) is treated with an enzyme capable of asymmetrically hydrolyzing an ester (which will be sometimes simply called an "enzyme” hereinafter) to thereby give the compound (II).
  • an enzyme capable of asymmetrically hydrolyzing an ester which will be sometimes simply called an "enzyme” hereinafter
  • another compound (III) is formed together with the compound (II) as shown in the following reaction scheme.
  • the acyloxy group at the 3-position and R 1 at the 4-position are in the cis-configuration.
  • the compound (I) is a racemate having the (3R, 4S) and (3S, 4R) forms
  • the compound (II) is in the (3R, 4S) form
  • the compound (III) is in the (3S, 4R) form. Since the (35, 4R) form of the compound (I) is selectively ester-hydrolyzed by the enzyme, the (3R, 4S) form of the compound (I) , namely, the compound (II) selectively remains.
  • the compound (II) may be separated from the mixture of the compound (II) with the compound (III) by usual recrystallization using a suitable solvent without resort to a column. It is advantageous that, even though R 3 COO at the 3-position of the compound (II) is ester-hydrolyzed into OH and a desired protective group is introduced thereinto, the R-configuration at the 3-position and the S-configuration at the 4-position are sustained, and even though the amino group at the 1-position is eliminated or protected, the R-configuration at the 3-position and the S-configuration at the 4-psotion are sustained. Owing to these characteristics, the above-described compound (1) can be formed without resort to optical resolution by using a column, whereby an extremely high efficiency can be established (see, Examples and Referential Examples).
  • the enzyme to be used in the present invention is not particularly restricted, so long as it is capable of stereo-selectively hydrolyzing the ester bond at the 3-position of the (3S, 4R) form of the compound (I).
  • a higher optical purity of the compound (III) obtained by the above-described reaction brings about the higher ester hydrolysis selectivity of the (3S, 4R) form of the compound (I). Therefore, it is favorable to employ such an enzyme.
  • the enzyme to be used in the present invention has an optical purity of the compound (III) of 80%ee or above, still preferably 90%ee or above and particularly preferably 95%ee or above.
  • a lipase is preferable. It is still preferable to use a lipase originating in a microorganism, for example, a lipase originating in a microorganism belonging to the genus Pseudomonas or Aspergillus .
  • an immobilized lipase examples thereof include lipases immobilized on ceramics or diatomaceous earth.
  • lipase As specific examples of the lipase, Amano PS, Amano PS-CI, Amano PS-DI and Amano AK (manufactured by Amano Enzyme), etc. may be cited.
  • the contact method is not particularly restricted, it is preferable to dissolve the compound (I) in an appropriate solvent and then bring the enzyme into contact with the compound (I).
  • the contact time of bringing the above-described enzyme into contact with the compound (I) may be properly determined to achieve the desired hydrolysis ratio and optical purity.
  • the reaction can proceed even if the contact time with the compound (I) is a short time.
  • the contact time is preferably 0.5 to 48 hours, more preferably 0.5 to 24 hours, and most preferably 0.5 to 18 hours.
  • the solvent is not particularly restricted, so long as it would not inhibit the ester-hydrolysis reaction as described above.
  • an organic solvent such as toluene, isopropyl ether, ethyl acetate, ethanol, acetonitrile, isopropyl ether, tetrahydrofuran, acetone, or a mixture thereof with water.
  • the mixing ratio (by volume) of water is 5% or more but not more than 80%.
  • the mixing ratio of water is preferably adjusted to 40%.
  • the reaction temperature may be properly determined depending on the solvent. Namely, the reaction temperature is preferably controlled to about 40°C in case of using an ethyl acetate or toluene-based solvent, or to about 25°C in case of using an ethanol-based solvent.
  • Stirring may be performed by using a stirrer, stirring blades, a shaker or the like.
  • An adequate device may be suitably selected.
  • the relation between the concentration of the substrate, i.e., the compound (I) and the amount of the enzyme may be suitably controlled.
  • the selectivity of the enzyme would be lowered with an increase in the substrate concentration.
  • the selectively would be lowered with a decrease in the enzyme amount. It is preferable to control the substrate concentration to about 5% and the enzyme amount to about 0.4 (enzyme mass/substrate mass).
  • the pH of the reaction system is usually adjusted to the optimum pH value of the enzyme during the reaction.
  • the initial pH value little differs from the pH value after the completion of the reaction. Thus, there arises a merit that no pH control is needed.
  • the enzyme is filtered off and the solvent is concentrated under reduced pressure. Then the residue is extracted with a solvent, concentrated under reduced pressure and recrystallized from an appropriate solvent.
  • the compound (II) can be obtained at a high purity (99% or above) and a high optical purity (99%ee or above).
  • Water-containing methanol is preferable as the solvent for crystallization.
  • a methanol/water mixture (17:19 by volume) is preferable therefor.
  • the compound (II) thus obtained is a novel optically active compound.
  • R 1 represents a phenyl group or a pyridyl group which may respectively have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
  • substituent selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
  • R 1 is a 3-fluoro-2-pyridyl group.
  • R 2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent(s) or an aralkyl group which may have substituent(s).
  • R 2 is a phenyl group or an aralkyl group.
  • the phenyl group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably an alkoxyl group.
  • the aralkyl group has a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s), and the aryl moiety may have one or more Substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group.
  • R 2 is a 4-methoxyphenyl group or a bis(4-methoxyphenyl)methyl group.
  • R 3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s). It is particularly preferable that R 3 is a methyl group.
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (480 g) was suspended in a mixture of ethanol (5.76 1) with 0.1 M phosphate buffer pH 7.0 (3.84 1) . Then an enzyme Lipase PS-CI (144 g) was added thereto and the mixture was stirred at 25°C for 16 hours. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (8.16 1) and water (9.18 1) and the mixture was stirred at 10°C for 16 hours.
  • Example 1a (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl) -2-azetidinone (1 g) was suspended in a mixture of ethanol (6 ml) with 0.1 M phosphate buffer pH 7.0 (4 ml). Then an enzyme Lipase PS-CI (1 g) was added thereto and the mixture was stirred at 25°C for 30 minutes. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (17 ml) and water (19 ml) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (400 mg, 99.9%ee) as pale brown crystals. The 1 H-NMR data of this product was identical with those of the compound obtained in Example 1.
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1- ⁇ bis(4-methoxyphenyl)methyl ⁇ -2-azetidinone 200 mg was suspended in a mixture of N,N-dimethylformamide (2 ml) with 0.1 M phosphate buffer pH 7.0 (18 ml). Then an enzyme Lipase PS-CI (200 mg) was added thereto and the mixture was stirred at 25°C for 2 days. Then the liquid reaction mixture was extracted with methylene chloride. The organic layer was washed with water and dried over anhydrous magnesium sulfate.
  • 3-fluoro-2-formylpyridine (6.2 g) and bis(4-methoxyphenyl)methylamine (12 g) were dissolved in toluene (30 ml). After adding anhydrous sodium sulfate (12 g), the resultant mixture was stirred at room temperature for 30 minutes. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to give an imine compound. A solution (60 ml) of the imine compound thus obtained and triethylamine (8.2 ml) in dichloromethane was cooled to -5°C.
  • an optically active compound (II) can be obtained from a racemic compound (I) merely by treating the compound (I) with an enzyme capable of asymmetrically hydrolyzing an ester.
  • an enzyme capable of asymmetrically hydrolyzing an ester capable of asymmetrically hydrolyzing an ester.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A process for producing a compound represented by the following formula (II) which comprises treating a compound represented by the following formula (I) (wherein R1, R2 and R3 represent each a specific substituent) with an enzyme capable of asymmetrically hydrolyzing an ester and the novel compound (II). The process of the present invention makes it possible to easily obtain an optically active 2-azetidinone derivative in a large amount at a low cost.

Description

    TECHNICAL FIELD
  • This invention relates to a process for producing a 2-azetidinone derivative.
  • BACKGROUND ART
  • 2-Azetidinone derivatives are important as reactive compounds for forming the subsituent at the 13-position of an anticancer compound having the following structure.
    Figure 00010001
  • As such a reactive compound, use is made of, for example, a compound (1) having the following structure (TIPS: triisopropylsilyl group, Boc: tertiary butoxycarbonyl group (hereinafter "tertiary" will be abbreviated as "t-", i.e., "t-butoxycarbonyl group")
    Figure 00010002
  • This compound (1) is obtained by subjecting a racemic compound (2) (PMP: paramethoxyphenyl group (4-methoxyphenyl group) , Ac: acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration):
    Figure 00020001
    to deprotection of Ac at the 3-position, conversion into TIPS, recrystallization, elimination of PMP at the 1-position, and separation by column chromatography (which will be sometimes abbreviated as column hereinafter) to give a compound (3):
    Figure 00020002
    followed by separation with the use of an optical resolution column and attachment of a protective group.
  • The process for obtaining the compound (1) from the racemic compound (2) suffers from a problem that troublesome procedures (epimerization, replacement of the solvent for recrystallization, isolation by the column, etc.) are needed and yet only a low yield can be achieved. To obtain the compound (1), there arises an additional problem that the compound (3) should be separated by using an optical resolution column in the step prior to the final step, which results in an increase in the cost in case of mass production.
  • The present invention aims at providing a production process whereby an optically active 2-azetidinone derivative can be easily produced in a large amount at a low cost.
  • DISCLOSURE OF THE INVENTION
  • The present inventors have found a production process whereby an optically active 2-azetidinone derivative can be efficiently produced in a large amount at a low cost by treating a racemic 2-azetidinone derivative with an enzyme capable of asymmetrically hydrolyzing an ester, thereby completing the present invention.
  • Accordingly, the present invention relates to a process for producing a compound represented by formula (II):
    Figure 00030001
    wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s) , an aryloyl group whi ch may have substituent(s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
    which comprises treating a compound represented by formula (I) with an enzyme capable of asymmetrically hydrolyzing an ester:
    Figure 00040001
    wherein R1, R2 and R3 are each as defined above.
  • The present invention further relates to the followings:
  • The above-described production process wherein R1 is a 3-fluoro-2-pyridyl group;
  • the above-described production process wherein R2 is a a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group);
  • the above-described production process wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl) methyl group;
  • the above-described production process wherein R3 is a methyl group;
  • the above-described production process wherein the enzyme is a lipase;
  • the above-described production process wherein the lipase is a lipase originating in a microorganism belonging to the genus Pseudomonas;
  • the above-described production process wherein the lipase is a lipase originating in a microorganism belonging to the genus Aspergillus;
  • the above-described production process wherein the lipase is immobilized;
  • a compound represented by formula (II):
    Figure 00060001
    wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s), an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
  • the above-described compound wherein R1 is a 3-fluoro-2-pyridyl group;
  • the above-described compound wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms , a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group);
  • the above-described compound wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl) methyl group;
  • the above-described compound wherein R3 is a methyl group, etc.
  • In the present invention, the compound represented by formula (I) (which will be called the compound (I) hereinafter and the same will apply to compounds represented by other formulae) is treated with an enzyme capable of asymmetrically hydrolyzing an ester (which will be sometimes simply called an "enzyme" hereinafter) to thereby give the compound (II). Usually another compound (III) is formed together with the compound (II) as shown in the following reaction scheme.
    Figure 00080001
  • It is preferable herein that in the compound (I), the acyloxy group at the 3-position and R1 at the 4-position are in the cis-configuration. In this case, the compound (I) is a racemate having the (3R, 4S) and (3S, 4R) forms, the compound (II) is in the (3R, 4S) form and the compound (III) is in the (3S, 4R) form. Since the (35, 4R) form of the compound (I) is selectively ester-hydrolyzed by the enzyme, the (3R, 4S) form of the compound (I) , namely, the compound (II) selectively remains. In case where the compound (II) has crystalline nature, the compound (II) may be separated from the mixture of the compound (II) with the compound (III) by usual recrystallization using a suitable solvent without resort to a column. It is advantageous that, even though R3COO at the 3-position of the compound (II) is ester-hydrolyzed into OH and a desired protective group is introduced thereinto, the R-configuration at the 3-position and the S-configuration at the 4-position are sustained, and even though the amino group at the 1-position is eliminated or protected, the R-configuration at the 3-position and the S-configuration at the 4-psotion are sustained. Owing to these characteristics, the above-described compound (1) can be formed without resort to optical resolution by using a column, whereby an extremely high efficiency can be established (see, Examples and Referential Examples).
  • The enzyme to be used in the present invention is not particularly restricted, so long as it is capable of stereo-selectively hydrolyzing the ester bond at the 3-position of the (3S, 4R) form of the compound (I).
  • A higher optical purity of the compound (III) obtained by the above-described reaction brings about the higher ester hydrolysis selectivity of the (3S, 4R) form of the compound (I). Therefore, it is favorable to employ such an enzyme.
  • It is preferable that the enzyme to be used in the present invention has an optical purity of the compound (III) of 80%ee or above, still preferably 90%ee or above and particularly preferably 95%ee or above.
  • As the enzyme to be used in the present invention, a lipase is preferable. It is still preferable to use a lipase originating in a microorganism, for example, a lipase originating in a microorganism belonging to the genus Pseudomonas or Aspergillus.
  • It is also preferable to use an immobilized lipase. Examples thereof include lipases immobilized on ceramics or diatomaceous earth.
  • As specific examples of the lipase, Amano PS, Amano PS-CI, Amano PS-DI and Amano AK (manufactured by Amano Enzyme), etc. may be cited.
  • To treat the compound (I) wi th the above-described enzyme, it is required to bring the compound (I) into contact wi th the enzyme. Although the contact method is not particularly restricted, it is preferable to dissolve the compound (I) in an appropriate solvent and then bring the enzyme into contact with the compound (I).
  • The contact time of bringing the above-described enzyme into contact with the compound (I) may be properly determined to achieve the desired hydrolysis ratio and optical purity. In the present invention, when an immobilized lipase is used as the enzyme, the reaction can proceed even if the contact time with the compound (I) is a short time. Illustratively, the contact time is preferably 0.5 to 48 hours, more preferably 0.5 to 24 hours, and most preferably 0.5 to 18 hours.
  • The solvent is not particularly restricted, so long as it would not inhibit the ester-hydrolysis reaction as described above. For example, use can be made of an organic solvent such as toluene, isopropyl ether, ethyl acetate, ethanol, acetonitrile, isopropyl ether, tetrahydrofuran, acetone, or a mixture thereof with water. In case of using a mixture of an organic solvent with water, it is preferable that the mixing ratio (by volume) of water is 5% or more but not more than 80%. In case of using ethanol as the organic solvent, the mixing ratio of water is preferably adjusted to 40%.
  • The reaction temperature may be properly determined depending on the solvent. Namely, the reaction temperature is preferably controlled to about 40°C in case of using an ethyl acetate or toluene-based solvent, or to about 25°C in case of using an ethanol-based solvent.
  • Stirring may be performed by using a stirrer, stirring blades, a shaker or the like. An adequate device may be suitably selected.
  • The relation between the concentration of the substrate, i.e., the compound (I) and the amount of the enzyme may be suitably controlled. In general, the selectivity of the enzyme would be lowered with an increase in the substrate concentration. Also, the selectively would be lowered with a decrease in the enzyme amount. It is preferable to control the substrate concentration to about 5% and the enzyme amount to about 0.4 (enzyme mass/substrate mass).
  • The pH of the reaction system is usually adjusted to the optimum pH value of the enzyme during the reaction. In the present invention, the initial pH value little differs from the pH value after the completion of the reaction. Thus, there arises a merit that no pH control is needed.
  • After the completion of the enzymatic reaction, the enzyme is filtered off and the solvent is concentrated under reduced pressure. Then the residue is extracted with a solvent, concentrated under reduced pressure and recrystallized from an appropriate solvent. Thus, the compound (II) can be obtained at a high purity (99% or above) and a high optical purity (99%ee or above).
  • Water-containing methanol is preferable as the solvent for crystallization. In particular, a methanol/water mixture (17:19 by volume) is preferable therefor.
  • The compound (II) thus obtained is a novel optically active compound.
  • In the compound (I) and the compound (II), the substituents R1, R2 and R3 remain unchanged after the reaction.
  • Next, the substituents R1, R2 and R3 will be illustrated in greater detail.
  • R1 represents a phenyl group or a pyridyl group which may respectively have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
  • It is particularly preferable that R1 is a 3-fluoro-2-pyridyl group.
  • R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent(s) or an aralkyl group which may have substituent(s).
  • It is preferable that R2 is a phenyl group or an aralkyl group. The phenyl group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably an alkoxyl group. The aralkyl group has a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s), and the aryl moiety may have one or more Substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group.
  • It is particularly preferable that R2 is a 4-methoxyphenyl group or a bis(4-methoxyphenyl)methyl group.
  • R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s). It is particularly preferable that R3 is a methyl group.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • Now, the present invention will be described in greater detail by reference to the following Examples, but the present invention should not be construed as being limited thereto.
  • Optical purity was determined under the following conditions.
       Column: ULTRON ES-OVM (150 mm x 4.6 mm), Shinwa Kako
       Mobile phase: MeOH:0.02M phosphate buffer pH 7.0=5:95
       Flow rate: 1.0 ml/min
       Temperature: 40°C
       Detection: 254 nm
       Retention time: desired (3R, 4S) ester: 17 min, (3S, 4R)    ester: 11 min, (3R, 4S) alcohol: 8.3 min,    (3R, 4S) alcohol: 9.3 min, trans-alcohol:    11, 31 min
  • Example 1: (3R, 4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (480 g) was suspended in a mixture of ethanol (5.76 1) with 0.1 M phosphate buffer pH 7.0 (3.84 1) . Then an enzyme Lipase PS-CI (144 g) was added thereto and the mixture was stirred at 25°C for 16 hours. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (8.16 1) and water (9.18 1) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (182 g, 99.7%ee) as pale brown crystals.
    1H-MMR (CDCl3)δ: 1.80 (s, 3H) , 3.74 (s, 3H) , 5.72 (d, 1H, J=5.6Hz), 6.09 (d, 1H, J=5.1Hz), 6.77-6.83 (m, 2H), 7.21-7.29 (m, 2H), 7.30-7.33 (m, 1H), 7.41-7.46 (m, 1H), 8.43-8.46 (m, 1H)
  • Example 1a: (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl) -2-azetidinone (1 g) was suspended in a mixture of ethanol (6 ml) with 0.1 M phosphate buffer pH 7.0 (4 ml). Then an enzyme Lipase PS-CI (1 g) was added thereto and the mixture was stirred at 25°C for 30 minutes. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (17 ml) and water (19 ml) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (400 mg, 99.9%ee) as pale brown crystals. The 1H-NMR data of this product was identical with those of the compound obtained in Example 1.
  • Examples 2 to 14:
  • Reactions were carried out as in Example 1 but employing different enzymes and reaction solvents in the asymmetric hydrolysis reaction.
    Ex. Enzyme Reaction Solvent (water content:5%) Optical Purity of Compound (III) (%ee) Reaction Ratio
    2 Amano PS toluene >95 >48
    3 Amano PS isopropyl ether 92 42
    4 Amano PS-CI ethyl acetate >95 >48
    5 Amano PS-CI toluene >95 >48
    6 Amano PS-CI ethanol >95 >48
    7 Amano PS-CI acetonitrile >95 36
    8 Amano PS-CI isopropyl ether 93 32
    9 Amano PS-CI tetrahydrofuran >95 37
    10 Amano PS-CI acetone 93 29
    11 Amano PS-DI toluene 93 26
    12 Amano PS-DI ethanol 93 22
    13 Amano PS-DI isopropyl ether 91 28
    14 Amano AK isopropyl ether 91 35
  • Example 15: (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-{bis(9-methoxyphenyl)methyl}-2-azetidinone
  • Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (200 mg) was suspended in a mixture of N,N-dimethylformamide (2 ml) with 0.1 M phosphate buffer pH 7.0 (18 ml). Then an enzyme Lipase PS-CI (200 mg) was added thereto and the mixture was stirred at 25°C for 2 days. Then the liquid reaction mixture was extracted with methylene chloride. The organic layer was washed with water and dried over anhydrous magnesium sulfate. After evaporating the solvent, the obtained residue was subjected to silica gel column to thereby give the title compound (90 mg, 99.7%ee) as a colorless oily product. Also, (3S,4R)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (96 mg, 99.5%ee) was obtained.
    1H-NMR (CDCl3)δ: 1 .75 (s, 3H) , 3.72 (s, 3H) 3.79 (s, 3H) , 5.30 (d, 1H, J=5Hz), 5.91 (s, 1H), 5.93 (d, 1H, J=5Hz), 6.64 (d, 2H, J=8.9Hz), 6.83 (d, 2H, J=8.9Hz), 7.06-7.20 (m, 6H), 8.35-8.42 (m, 1H)
  • Referential Example 1: N-[(E)-(3-fluoro-2-pyridyl)methylidene]-4-methoxyaniline
  • 3-Fluoro-2-formylpyridine (229 g) and paraanisidine (225 g) were dissolved in toluene (2.29 l). After adding anhydrous sodium sulfate (334 g) , the mixture was stirred at room temperature for 1 hour. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to thereby give the title compound (449 g).
    1H-NMR (CDCl3) δ: 3.85 (s, 3H) , 6.96 (d, J=8.9Hz, 2H) , 7.41 (d, J=8.9Hz, 2H), 7.36-7.43 (m, 1H), 7.53 (m, 1H), 8.62 (d, J=4.3Hz, 1H), 8.86 (s, 1H)
  • Referential Example 2 : Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
  • A solution (2.29 l) of N-[(E)-(3-fluoro-2-pyridyl)methylidene]-4-methoxyaniline (449 g) and triethylamine (204 g) in dichloromethane was cooled to -10°C. Then acetoxyacetyl chloride (250 g) was added dropwise thereinto and the resultant mixture was stirred at the same temperature for 30 minutes. Then it was heated to room temperature and stirred for 16 hours . The liquid reaction mixture was washed with water and the solvent was concentrated under reduced pressure to thereby give a crude product (723 g). This crude product was recrystallized from a solvent mixture of ethanol (6.91) and ethyl acetate (350 ml) to thereby give the title compound (486 g) as brown crystals.
    1H-NMR (CDCl3)δ: 1.80 (s, 3H), 3.74 (s, 3H), 5.72 (d, 1H, J=5.6Hz), 6. 09 (d, 1H, J=5.1Hz), 6.77-6.83 (m, 2H) , 7.21-7.29 (m, 2H) , 7.30-7.33 (m, 1H, 7.41-7 .46 (m, 1H), 8.43-8.46 (m, 1H).
  • Referential Example 3: Cis-3-acetoxy-4- (3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone
  • Under a nitrogen gas stream, 3-fluoro-2-formylpyridine (6.2 g) and bis(4-methoxyphenyl)methylamine (12 g) were dissolved in toluene (30 ml). After adding anhydrous sodium sulfate (12 g), the resultant mixture was stirred at room temperature for 30 minutes. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to give an imine compound. A solution (60 ml) of the imine compound thus obtained and triethylamine (8.2 ml) in dichloromethane was cooled to -5°C. Then acetoxyacetyl chloride (6.3 ml) was added dropwise thereinto and the resultant mixture was stirred at the same temperature for 30 minutes. Then it was heated to room temperature and stirred for 16 hours. The liquid reaction mixture was washed with water and then extracted with chloroform. The organic layers were combined, washed with water and dried over anhydrous magnesium sulfate. After concentrating the solvent under reduced pressure, ethyl acetate (20 ml) and diisopropyl ether (60 ml) were added to the obtained residue. The resultant mixture was stirred at room temperature. The crystals thus precipitated were collected by filtration to thereby give the title compound (21.8 g) as white crystals.
    1H-NMR (CDCl3)δ: 1.75 (s, 3H) , 3.72 (s, 3H) , 3.79 (s, 3H) , 5.30 (d, 1H, J=5Hz) , 5.91 (s, 1H) , 5.93 (d, 1H, J=5Hz) , 6.64 (d, 2H, J=8.9Hz), 6.83 (d, 2H, J=8.9Hz), 7.06-7.20 (m, 6H), 8.35-8.42 (m, 1H)
  • Referential Example 4: (3R, 4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
  • (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (181 g, 99.7%ee) was dissolved in a solvent mixture of methylene chloride (725 ml) and methanol (725 ml). After adding potassium carbonate (5.43 g) at 0°C, the resultant mixture was stirred at the same temperature for 1 hour. Then Dowex 50 (27 g) was added to the liquid reaction mixture followed by stirring. After filtering off the insoluble matters, the solvent was evaporated. Then toluene was added to the obtained residue and the mixture was azeotropically distilled. Thus, the title compound (157.9 g, 99.7%ee) was obtained as white crystals.
    1H-NMR (CDCl3)δ: 3.74 (s, 3H), 5.34 (d, 1H, J=5Hz), 5.62 (dd, 1H, J=5, 1Hz) , 6.78-6.81 (m, 2H) , 7.15-7.38 (m, 3H), 7.52-7.59 (m, 1H) , 8.45-8.47 (m, 1H)
  • Referential Example 5: (3R, 4S)-cis-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-3-triisopropylsilyloxy-2-azetidinone
  • (3R,4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (126.5 g, 99.7%ee) was dissolved in methylene chloride (1.45 1). After adding triisopropylsilyl chloride (118 g) and imidazole (75 g), the resultant mixture was stirred at room temperature for 12 hours. After washing with water, the liquid reaction mixture was dried over anhydrous magnesium sulfate. Then the solvent was evaporated and n-hexane was added to the obtained residue. The mixture was stirred at room temperature for 2 hours and then at 0°C for 2 hours. The crystals thus precipitated were collected by filtration. Thus, the title compound (176 g, 99.7%ee) was obtained as white crystals.
    1H-NMR (CDCl3)δ: 0.91-1.06 (m, 21H), 3.74 (s, 3H) , 5.38 (d, 1H, J=5.1Hz), 5 . 50 (d, 1H, J=4.9Hz), 6.78-6.81 (m, 2H) , 7.23-7.30 (m, 3H), 7.35-7.39 (m, 1H), 8.41-8.43 (m, 1H).
  • Referential Example 6: (3R,4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone
  • (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-{bis( 4-methoxyphenyl)methyl}-2-azetidinone (90 mg, 99.5%ee) was dissolved in a solvent mixture of tetrahydrofuran (0.3 ml), methanol (0.3. ml) and methylene chloride (0.3 ml). After adding potassium carbonate (2 .3 mg), the resultant mixture was stirred at 0°C for 1 hour and 30 minutes. Then Dowex 50 (10 mg) was added to the liquid reaction mixture followed by stirring for 5 minutes. After filtering off the insoluble matters, the solvent was evaporated. Thus, the title compound (81.6 mg, 99.5%ee) was obtained as a colorless oily product.
    1H-NMR (CDCl3)δ: 3.70 (s, 3H) , 3.81 (s, 3H) , 5.08-5.27 (m, 2H), 5.94 (s, 1H), 6.55 (d, 2H, J=8.6Hz), 6.85 (d, 2H, J=8.6Hz), 7.15-7.20 (m, 6H), 8.36-8.41 (m, 1H)
  • Referential Example 7: (3R, 4S)-cis-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-3-triisopropylsilyloxy-2-azetidinone
  • (3R,4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (81.6 mg, 99.5%ee) was dissolved in methylene chloride (1 ml). After adding triisopropylsilyl chloride (55.3 µl) and imidazole (20.4 mg), the resultant mixture was stirred at room temperature for 16 hours . After washing with water, the liquid reaction mixture was dried over anhydrous magnesium sulfate. Then the solvent was evaporated. Thus, the title compound (112.8 mg, 99.5%ee) was obtained as a colorless oily product.
    1H-NMR (CDCl3) δ: 0.62-1:00 (m, 21H) , 3.69 (s, 3H), 3.78 (s, 3H), 5.15 (d, 1H, J=5Hz), 5.29 (d, 2H, J=5Hz), 5.93 (s, 1H), 6.62 (d, 2H, J-8.6Hz), 6.84 (d, 2H, J=8. 6Hz), 7.05-7.19 (m, 3H), 8.31-8.34 (m, 1H)
  • Referential Example 8: (3R, 4S)-cis-4-(3-fluoro-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone
  • (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-3-triisopropylsilyloxy-2-azetidinone (167 g, 99.7%ee) was dissolved in acetonitrile (5 1) and then cooled to -10°C. After adding an aqueous solution (5 1) of ammonium cerium nitrate (515 g), the resultant mixture was stirred at the same temperature for 30 minutes. After adding diisopropyl ether, the liquid reaction mixture was washed with water, a 4% aqueous sodium thiosulfate solution and a 2% aqueous sodium hydrogencarbonate solution. After evaporating the solvent, the obtained residue was dissolved in methanol (1.67 l). Then active carbon (167 g) was added and the resultant mixture was stirred at room temperature for 16 hours. After filtering off the active carbon, the solvent was evaporated. To the obtained residue were added ethanol (835 ml) and water (1.25 l). Then the mixture was stirred at room temperature for 5 hours. The crystals thus precipitated were collected by filtration to thereby give the title compound (97.5 g, 99.7%ee) as white crystals.
    1H-NMR (CDCl3)δ: 0.89-1.08 (m, 21H), 5.71 (dd, 1H, J=4.8, 1.4Hz), 5.35 (dd, 1H, J=4.9, 1.5Hz) , 6.18 (brs, 1H), 7.22-7.26 (m, 1H), 7.33-7.41 (m, 1H), 8.42-8.44 (m, 1H)
  • Referential Example 9: (3R, 4S)-cis-4-(3-fluoro-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone
  • (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-3-triisopropylsilyloxy-2-azetidinone (112.8 mg, 99.5%ee) was dissolved in acetonitrile (0.56 ml) and then cooled to -10°C. After adding an aqueous solution (4 ml) of ammonium cerium nitrate (346 mg), the resultant mixture was stirred at the same temperature for 30 minutes. After adding chloroform, the liquid reaction mixture was washed with water and dried over anhydrous magnesium sulfate. After evaporating the solvent, the obtained residue was subjected to silica gel column chromatography to thereby give the title compound (59.2 mg, 99.5%ee) as white crystals. The 1H-NMR data of this product was identical with those obtained in Referential Example 8.
  • Referential Example 10: (3R, 4S)-cis-1-(t-butoxycarbonyl)-4-(3-fluoro-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone
  • (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone (44.9 g, 99.7%ee) was dissolved in tetrahydrofuran (448.6 ml). After adding 4-dimethylaminopyridine (1.62 g) and di-t-butyl dicarbonate (36.5 ml) at room temperature, the resultant mixture was stirred at the same temperature for 1 hour. After adding n-hexane, the liquid reaction mixture was washed with a 4% aqueous sodium hydrogencarbonate solution and water. The organic layer was dried over anhydrous magnesium sulfate. After evaporating the solvent, the title compound (58.1 g, 99.7%ee) was obtained as a brown oily product.
    1H-NMR (CDCl3)δ: 0. 88-1 .02 (21H, m), 1 .44 (9H, s), 5.27 (1H, d, J=5.6Hz), 5.45 (1H, d, J=5.6Hz), 7.23-7.28 (1H, m), 7.34-7.41 (1H, m), 8.41-8.44 (1H, m)
  • INDUSTRIAL APPLICABILITY
  • According to the present invention, an optically active compound (II) can be obtained from a racemic compound (I) merely by treating the compound (I) with an enzyme capable of asymmetrically hydrolyzing an ester. Thus, the process of the present invention makes it possible to efficiently obtain the compound (II) in a large amount at a low cost.

Claims (14)

  1. A process for producing a compound represented by formula (II):
    Figure 00250001
    wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s), an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
    which comprises treating a compound represented by formula (I) with an enzyme capable of asymmetrically hydrolyzing an ester:
    Figure 00260001
    wherein R1, R2 and R3 are each as defined above.
  2. The process according to claim 1 wherein R1 is a 3-fluoro-2-pyridyl group.
  3. The process according to claim 1 or 2 wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group).
  4. The process according to any of claims 1 to 3 wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl)methyl group.
  5. The process according to any of claims 1 to 4 wherein R3 is a methyl group.
  6. The process according to any of claims 1 to 5 wherein the enzyme is a lipase.
  7. The process according to claim 6 wherein the lipase is a lipase originating in a microorganism belonging to the genus Pseudomonas.
  8. The process according to claim 6 wherein the lipase is a lipase originating in a microorganism belonging to the genus Aspergillus.
  9. The process according to claim 7 or 8 wherein the lipase is immobilized.
  10. A compound represented by formula (II):
    Figure 00270001
    wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s).
  11. The compound according to claim 10 wherein R1 is a 3-fluoro-2-pyridyl group.
  12. The compound according to claim 10 or 11 wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group).
  13. The compound according to any of claims 10 to 12 wherein R2 is a 4-methoxyphenyl group or bis(4-methoxyphenyl)methyl group.
  14. The compound according to any of claims 10 to 13 wherein R3 is a methyl group.
EP02705071A 2001-03-07 2002-03-04 Method for producing a 2-azetidinone derivative Expired - Lifetime EP1375495B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001063840 2001-03-07
JP2001063840 2001-03-07
PCT/JP2002/001969 WO2002070512A1 (en) 2001-03-07 2002-03-04 Method for producing 2-azetidinone derivative

Publications (3)

Publication Number Publication Date
EP1375495A1 true EP1375495A1 (en) 2004-01-02
EP1375495A4 EP1375495A4 (en) 2005-03-09
EP1375495B1 EP1375495B1 (en) 2008-09-03

Family

ID=18922762

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02705071A Expired - Lifetime EP1375495B1 (en) 2001-03-07 2002-03-04 Method for producing a 2-azetidinone derivative

Country Status (13)

Country Link
US (1) US7126003B2 (en)
EP (1) EP1375495B1 (en)
JP (1) JP4142444B2 (en)
KR (1) KR100851515B1 (en)
CN (1) CN1266148C (en)
AT (1) ATE407130T1 (en)
DE (1) DE50212728D1 (en)
ES (1) ES2311591T3 (en)
HK (1) HK1058668A1 (en)
MY (1) MY139322A (en)
NO (1) NO20033917L (en)
TW (1) TWI311135B (en)
WO (1) WO2002070512A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295229C (en) * 2001-11-29 2007-01-17 第一制药株式会社 Crystals of taxane derivative and process for their production
CN100494204C (en) * 2006-01-12 2009-06-03 上海交通大学 (1'R,3R, 4R)-4-acetoxy-3-(1-tert-butyldimethylsiloxyethyl) azetidin-2-one oxidation synthesis method
US8785669B2 (en) 2010-06-30 2014-07-22 Gfv, Llc Taxane compounds, compositions and methods
US8697892B2 (en) 2010-06-30 2014-04-15 Gfv, Llc Taxane compounds, compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0582469A2 (en) * 1992-08-06 1994-02-09 Wisconsin Alumni Research Foundation Process for preparing taxol-type compound from beta-lactam precursors
EP1001036A2 (en) * 1992-01-15 2000-05-17 E.R. Squibb & Sons, Inc. Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
WO2001029245A2 (en) * 1999-10-18 2001-04-26 Florida State University ENZYMATIC PROCESS FOR THE RESOLUTION OF ENANTIOMERIC MIXTURES OF β-LACTAMS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0679559B2 (en) * 1985-06-06 1994-10-12 三共株式会社 Process for producing optically active azetidinone derivative
FR2688499B1 (en) * 1992-03-10 1994-05-06 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE AND ITS ANALOGS.
TW397866B (en) * 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
JP3703519B2 (en) * 1994-05-31 2005-10-05 株式会社クラレ Method for producing optically active substance
JP2779386B2 (en) 1995-11-01 1998-07-23 株式会社カンキョー Total heat exchange ventilator
DE19605024A1 (en) 1996-01-31 1997-08-07 Schering Ag New selective taxanes, processes for their preparation and their pharmaceutical use
EP0933360A1 (en) * 1997-12-22 1999-08-04 Pharmachemie B.V. Synthesis of new beta-lactams
US6677456B2 (en) * 1999-10-15 2004-01-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic taxan compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001036A2 (en) * 1992-01-15 2000-05-17 E.R. Squibb & Sons, Inc. Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
EP0582469A2 (en) * 1992-08-06 1994-02-09 Wisconsin Alumni Research Foundation Process for preparing taxol-type compound from beta-lactam precursors
WO2001029245A2 (en) * 1999-10-18 2001-04-26 Florida State University ENZYMATIC PROCESS FOR THE RESOLUTION OF ENANTIOMERIC MIXTURES OF β-LACTAMS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO02070512A1 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

Also Published As

Publication number Publication date
US7126003B2 (en) 2006-10-24
MY139322A (en) 2009-09-30
NO20033917D0 (en) 2003-09-04
ATE407130T1 (en) 2008-09-15
ES2311591T3 (en) 2009-02-16
WO2002070512A1 (en) 2002-09-12
EP1375495B1 (en) 2008-09-03
EP1375495A4 (en) 2005-03-09
JPWO2002070512A1 (en) 2004-07-02
JP4142444B2 (en) 2008-09-03
CN1266148C (en) 2006-07-26
NO20033917L (en) 2003-10-31
US20040072309A1 (en) 2004-04-15
KR100851515B1 (en) 2008-08-11
CN1507443A (en) 2004-06-23
KR20030080072A (en) 2003-10-10
TWI311135B (en) 2009-06-21
HK1058668A1 (en) 2004-05-28
DE50212728D1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
EP1375495B1 (en) Method for producing a 2-azetidinone derivative
JP2012211136A (en) Improved method for preparing 3-hydroxy-4-hydroxymethyl pyrrolidine compound
KR100914396B1 (en) Process for the preparation of benzoxazine derivatives and intermediates therefor
JP2011510038A (en) Production method using ((2S, 4R) -4,6-dihydroxytetrahydro-2H-pyran-2-yl) methylcarboxylate and 2-deoxyribose-5-phosphate aldolase
JPH06172276A (en) Manufacture of taxol compound from beta - lactam precursor
US5527916A (en) Pyranones
RU2414459C2 (en) Method of producing diaryl cycloalkyl derivatives
JP2005176758A (en) Method for producing 4-oxochroman-2-carboxylic acid derivative having optical activity
JP5216762B2 (en) Stereoselective synthesis of (S) -1-methyl-phenylpiperazine
US5731464A (en) Process for preparation of indenol
EP1283200A2 (en) Optically pure paroxetine precursors
CN1768149B (en) Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives
US6020174A (en) Chemoenzymatic synthesis of the taxol C-13 side chain N-benzolyl- (2R,3S)-Phenylisoserine
KR20070076549A (en) Processes for the preparations of optically active cyclopentenones and cyclopentenones prepared therefrom
JPS62272983A (en) Production of l-(-)-carnitine chloride starting from 3, 4-epoxybutyric ester
KR20030074851A (en) Resolution of chiral compounds using aminocyclopentadienyl ruthenium catalysts
JP2666890B2 (en) Method for producing optically active (+)-4,4,4-trifluoro-3- (indole-3-) butyric acid
KR20060060730A (en) Enzymatic synthesis of enantiopure intermediates by means of cholesterolesterase from yeasts
KR100359028B1 (en) Method for preparing chiral allyl ester
JPH05279370A (en) Optically active camptothecin derivative and its production
JPH0679559B2 (en) Process for producing optically active azetidinone derivative
US6037166A (en) Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics
AU2004219845A1 (en) Stereoselective chemoenzymatic process for the preparation of optically enriched phenylglycidates as precursors of taxol side chain
EP0617130A2 (en) Method for the resolution of racemic mixtures
EP0537921A2 (en) Enzymatic synthesis of chiral alpha-hydroxyketones and derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1058668

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20050121

17Q First examination report despatched

Effective date: 20061127

RTI1 Title (correction)

Free format text: METHOD FOR PRODUCING A 2-AZETIDINONE DERIVATIVE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAIICHI SANKYO COMPANY, LIMITED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 50212728

Country of ref document: DE

Date of ref document: 20081016

Kind code of ref document: P

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1058668

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2311591

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090203

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

26N No opposition filed

Effective date: 20090604

BERE Be: lapsed

Owner name: DAIICHI SANKYO COMPANY, LTD

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081204

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: DAIICHI SANKYO COMPANY, LIMITED

Free format text: DAIICHI SANKYO COMPANY, LIMITED#3-5-1, NIHOMBASHI-HONCHO CHUO-KU#TOKYO 103-8426 (JP) -TRANSFER TO- DAIICHI SANKYO COMPANY, LIMITED#3-5-1, NIHOMBASHI-HONCHO CHUO-KU#TOKYO 103-8426 (JP)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080903

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210113

Year of fee payment: 20

Ref country code: CH

Payment date: 20210317

Year of fee payment: 20

Ref country code: IE

Payment date: 20210310

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210216

Year of fee payment: 20

Ref country code: GB

Payment date: 20210225

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20210406

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20210211

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 50212728

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220303

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220303

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220304

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220305